Accurie Biosciences is developing a platform (enPhaG®) that creates artificially synthesized phages targeting specific bacteria, using a virtual phage database discovered through human genome analysis — without isolating phages from nature. Leveraging this platform, the company is developing combination therapies for solid tumors that effectively deliver drugs to the tumor microenvironment, as well as treatments for microbiome-related immune diseases and infectious diseases.